Kiadis Pharma to present at upcoming conference in August 2019
Kiadis Pharma NV (EU:KDS)
Graphique Historique de l'Action
De Mai 2019 à Mai 2020
Kiadis Pharma to present at upcoming conference in
Amsterdam, The Netherlands, July 31, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces it is scheduled to attend the following conference in August 2019.
Cannacord Genuity 39th Annual Growth ConferenceAugust 7-8, 2019, Boston, MA
Management will present on August 7th at 09.00-09.25am EDT and will host meetings.
A live webcast of the presentation will be available here: http://wsw.com/webcast/canaccord35/kds/ An archived replay of the webcast will be available on the Company's website for approximately 90 days following the presentation.
|Kiadis Pharma:Maryann Cimino, Manager, Corporate AffairsTel. +1 617 710 email@example.com||Optimum Strategic Communications:Mary Clark, Supriya Mathur, Hollie VileTel: +44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942 firstname.lastname@example.org|
About Kiadis PharmaFounded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with late-stage blood cancers. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.
Forward Looking StatementsCertain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.